Wang Zichun, Wang Xiaoxiong, Zhang Daming, Yu Yongchun, Cai Licheng, Zhang Cheng
1 Department of Urology, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
2 Department of Neurosurgery, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
Tumour Biol. 2017 Jun;39(6):1010428317709990. doi: 10.1177/1010428317709990.
To investigate the diagnostic value of urothelial carcinoma-associated 1 as a urine biomarker in urinary bladder cancer patients by performing a comprehensive meta-analysis. A comprehensive literature search was conducted by the databases PubMed, Embase, Cochrane Library, China Knowledge Resource Integrated, and Web of Science. The quality of eligible studies was scored with the Quality Assessment of Diagnostic Accuracy Studies. The bivariate meta-analysis model was used to pool the sensitivity, specificity, likelihood ratio, and diagnostic odds ratio. Receiver operating characteristic curves and hierarchical summary receiver operating characteristic models were employed to check the overall test performance in this meta-analysis. Seven publications involving 678 patients and 563 controls were included in this meta-analysis. The pooled sensitivity was 0.84 (95% confidence interval: 0.80-0.88), specificity was 0.87 (95% confidence interval: 0.75-0.94), positive likelihood ratio was 6.5 (95% confidence interval: 3.10-13.62), negative likelihood ratio was 0.18 (95% confidence interval: 0.13-0.25), and diagnostic odds ratio was 36 (95% confidence interval: 13-99). The area under the summary receiver operating characteristic curve was 0.89 (95% confidence interval: 0.86-0.91). Our results indicated that urothelial carcinoma-associated 1 was a potential diagnostic biomarker with good specificity and sensitivity in urinary bladder cancer. Further prospective studies with larger cohorts are necessary to evaluate the diagnostic accuracy of urothelial carcinoma-associated 1 for urinary bladder cancer.
通过进行全面的荟萃分析，探讨尿路上皮癌相关蛋白1作为膀胱癌患者尿液生物标志物的诊断价值。通过PubMed、Embase、Cochrane图书馆、中国知网和Web of Science数据库进行全面的文献检索。采用诊断准确性研究质量评估对纳入研究的质量进行评分。使用双变量荟萃分析模型汇总敏感性、特异性、似然比和诊断比值比。采用受试者工作特征曲线和分层汇总受试者工作特征模型来检验本荟萃分析中的总体检验性能。本荟萃分析纳入了7篇涉及678例患者和563例对照的文献。汇总敏感性为0.84（95%置信区间：0.80 - 0.88），特异性为0.87（95%置信区间：0.75 - 0.94），阳性似然比为6.5（95%置信区间：3.10 - 13.62），阴性似然比为0.18（95%置信区间：0.13 - 0.25），诊断比值比为36（95%置信区间：13 - 99）。汇总受试者工作特征曲线下面积为0.89（95%置信区间：0.86 - 0.91）。我们的结果表明，尿路上皮癌相关蛋白1是一种在膀胱癌中具有良好特异性和敏感性的潜在诊断生物标志物。需要进一步开展更大样本量队列的前瞻性研究，以评估尿路上皮癌相关蛋白1对膀胱癌的诊断准确性。
